Dynamic MicroRNA Activity Identifies Therapeutic Targets in Trastuzumab-resistant HER2 Breast Cancer

Overview

Journal Biotechnol Bioeng

Publisher Wiley

Specialty Biochemistry

Date 2018 Jul 8

PMID 29981261

Citations 9

Authors

Joseph T Decker

Matthew S Hall

Rachel B Blaisdell

Kallen Schwark

Jacqueline S Jeruss

Lonnie D Shea

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRNAs) are implicated in numerous physiologic and pathologic processes, such as the development of resistance to chemotherapy. Determining the role of miRNAs in these processes is often accomplished through measuring miRNA abundance by polymerase chain reaction, sequencing, or microarrays. We have developed a system for the large-scale monitoring of dynamic miRNA activity and have applied this system to identify the contribution miRNA activity to the development of trastuzumab resistance in a cell model of HER2 breast cancer. MiRNA activity measurements identified significantly different activity levels between BT474 cells (HER2 breast cancer) and BT474R cells (HER2 breast cancer cells selected for resistance to trastuzumab). We created a library of 32 miRNA reporter constructs, which were delivered by lentiviral transduction into cells, and miRNA activity was quantified by bioluminescence imaging. Upon treatment with the bioimmune therapy, trastuzumab, the activity of 11 miRNAs were significantly altered in parental BT474 cells, and 20 miRNAs had significantly altered activity in the therapy-resistant BT474R cell line. A combination of statistical, network and classification analysis was applied to the dynamic data, which identified miR-21 as a controlling factor in trastuzumab response. Our data suggested downregulation of miR-21 activity was associated with resistance, which was confirmed in an additional HER2 breast cancer cell line, SKBR3. Collectively, the dynamic miRNA activity measurements and analysis provided a system to identify new potential therapeutic targets in treatment-resistant cancers.

Citing Articles

Dynamic Transcriptional Programs During Single NK Cell Killing: Connecting Form to Function in Cellular Immunotherapy.

Decker J, Hall M, Nanua D, Orbach S, Roy J, Angadi A Cell Mol Bioeng. 2024; 17(3):177-188.

PMID: 39050513 PMC: 11263395. DOI: 10.1007/s12195-024-00812-3.

Circulating Plasma miRNA Homologs in Mice and Humans Reflect Familial Cerebral Cavernous Malformation Disease.

Romanos S, Srinath A, Li Y, Xie B, Chen C, Li Y Transl Stroke Res. 2022; 14(4):513-529.

PMID: 35715588 PMC: 9758276. DOI: 10.1007/s12975-022-01050-3.

Suspension state and shear stress enhance breast tumor cells EMT through YAP by microRNA-29b.

Zhao B, Lv Y Cell Biol Toxicol. 2021; 39(3):1037-1052.

PMID: 34618275 DOI: 10.1007/s10565-021-09661-6.

Regulatory Interplay between miR-181a-5p and Estrogen Receptor Signaling Cascade in Breast Cancer.

Benedetti R, Papulino C, Sgueglia G, Chianese U, De Marchi T, Iovino F Cancers (Basel). 2021; 13(3).

PMID: 33535487 PMC: 7867078. DOI: 10.3390/cancers13030543.

Cyclin E overexpression confers resistance to trastuzumab through noncanonical phosphorylation of SMAD3 in HER2+ breast cancer.

Decker J, Kandagatla P, Wan L, Bernstein R, Ma J, Shea L Cancer Biol Ther. 2020; 21(11):994-1004.

PMID: 33054513 PMC: 7678934. DOI: 10.1080/15384047.2020.1818518.

References

Ma L, Teruya-Feldstein J, Weinberg R . Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007; 449(7163):682-8. DOI: 10.1038/nature06174. View

Haury A, Mordelet F, Vera-Licona P, Vert J . TIGRESS: Trustful Inference of Gene REgulation using Stability Selection. BMC Syst Biol. 2012; 6:145. PMC: 3598250. DOI: 10.1186/1752-0509-6-145. View

Decker J, Hobson E, Zhang Y, Shin S, Thomas A, Jeruss J . Systems analysis of dynamic transcription factor activity identifies targets for treatment in Olaparib resistant cancer cells. Biotechnol Bioeng. 2017; 114(9):2085-2095. PMC: 5522358. DOI: 10.1002/bit.26293. View

Berns K, Horlings H, Hennessy B, Madiredjo M, Hijmans E, Beelen K . A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007; 12(4):395-402. DOI: 10.1016/j.ccr.2007.08.030. View

Yan L, Huang X, Shao Q, Huang M, Deng L, Wu Q . MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 2008; 14(11):2348-60. PMC: 2578865. DOI: 10.1261/rna.1034808. View

Wellner U, Schubert J, Burk U, Schmalhofer O, Zhu F, Sonntag A . The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009; 11(12):1487-95. DOI: 10.1038/ncb1998. View

Rohart F, Gautier B, Singh A, Le Cao K . mixOmics: An R package for 'omics feature selection and multiple data integration. PLoS Comput Biol. 2017; 13(11):e1005752. PMC: 5687754. DOI: 10.1371/journal.pcbi.1005752. View

Filipowicz W, Bhattacharyya S, Sonenberg N . Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?. Nat Rev Genet. 2008; 9(2):102-14. DOI: 10.1038/nrg2290. View

Nilsson S, Moller C, Jirstrom K, Lee A, Busch S, Lamb R . Downregulation of miR-92a is associated with aggressive breast cancer features and increased tumour macrophage infiltration. PLoS One. 2012; 7(4):e36051. PMC: 3338574. DOI: 10.1371/journal.pone.0036051. View

10.

Tavazoie S, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos P . Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008; 451(7175):147-52. PMC: 2782491. DOI: 10.1038/nature06487. View

11.

Slamon D, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344(11):783-92. DOI: 10.1056/NEJM200103153441101. View

12.

Nagata Y, Lan K, Zhou X, Tan M, Esteva F, Sahin A . PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004; 6(2):117-27. DOI: 10.1016/j.ccr.2004.06.022. View

13.

Iorio M, Ferracin M, Liu C, Veronese A, Spizzo R, Sabbioni S . MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16):7065-70. DOI: 10.1158/0008-5472.CAN-05-1783. View

14.

Yang S, Huang C, Li X, Yu M, He Y, Li J . miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. Toxicology. 2013; 306:162-8. DOI: 10.1016/j.tox.2013.02.014. View

15.

Muller V, Gade S, Steinbach B, Loibl S, von Minckwitz G, Untch M . Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. Breast Cancer Res Treat. 2014; 147(1):61-8. DOI: 10.1007/s10549-014-3079-3. View

16.

Scaltriti M, Eichhorn P, Cortes J, Prudkin L, Aura C, Jimenez J . Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci U S A. 2011; 108(9):3761-6. PMC: 3048107. DOI: 10.1073/pnas.1014835108. View

17.

Robinson S, Glonek G, Koch I, Thomas M, Davies C . Alignment of time course gene expression data and the classification of developmentally driven genes with hidden Markov models. BMC Bioinformatics. 2015; 16:196. PMC: 4472167. DOI: 10.1186/s12859-015-0634-9. View

18.

Kozomara A, Griffiths-Jones S . miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2013; 42(Database issue):D68-73. PMC: 3965103. DOI: 10.1093/nar/gkt1181. View

19.

Nahta R, Yu D, Hung M, Hortobagyi G, Esteva F . Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006; 3(5):269-80. DOI: 10.1038/ncponc0509. View

20.

Mullokandov G, Baccarini A, Ruzo A, Jayaprakash A, Tung N, Israelow B . High-throughput assessment of microRNA activity and function using microRNA sensor and decoy libraries. Nat Methods. 2012; 9(8):840-6. PMC: 3518396. DOI: 10.1038/nmeth.2078. View